1. Home
  2. TLSA vs ABOS Comparison

TLSA vs ABOS Comparison

Compare TLSA & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

N/A

Current Price

$0.68

Market Cap

145.1M

Sector

Health Care

ML Signal

N/A

Logo Acumen Pharmaceuticals Inc.

ABOS

Acumen Pharmaceuticals Inc.

N/A

Current Price

$0.19

Market Cap

165.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TLSA
ABOS
Founded
2013
1996
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
145.1M
165.6M
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
TLSA
ABOS
Price
$0.68
$0.19
Analyst Decision
Strong Buy
Hold
Analyst Count
2
6
Target Price
★ $7.87
$1.00
AVG Volume (30 Days)
522.3K
★ 5.5M
Earning Date
05-01-2026
10-26-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.55
$0.19
52 Week High
$1.90
$3.60

Technical Indicators

Market Signals
Indicator
TLSA
ABOS
Relative Strength Index (RSI) 46.12 21.33
Support Level $0.57 N/A
Resistance Level $1.21 $2.82
Average True Range (ATR) 0.10 0.03
MACD 0.01 0.02
Stochastic Oscillator 55.24 11.42

Price Performance

Historical Comparison
TLSA
ABOS

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.

About ABOS Acumen Pharmaceuticals Inc.

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.

Share on Social Networks: